This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AMP as a Better Delivery System of Adenosine

This study has suspended participant recruitment.
(In process of renewing IND for AMP)
Information provided by (Responsible Party):
Italo Biaggioni, Vanderbilt University Identifier:
First received: September 13, 2005
Last updated: February 2, 2015
Last verified: February 2015
Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.

Condition Intervention
Ischemia Drug: Adenosine Drug: Adenosine Mono Phosphate (AMP)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Official Title: Use of AMP to Improve Tissue Delivery of Adenosine

Resource links provided by NLM:

Further study details as provided by Italo Biaggioni, Vanderbilt University:

Primary Outcome Measures:
  • Interstitial adenosine levels [ Time Frame: Duration of ia infusion ]
  • Forearm blood flow [ Time Frame: Duration of ia infusion ]

Estimated Enrollment: 64
Study Start Date: October 2003
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Intrarterial infusion of adenosine
Drug: Adenosine
Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
Experimental: 2
Intrarterial infusion of AMP
Drug: Adenosine Mono Phosphate (AMP)
Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers
  • Age 18-65
  • Non smokers

Exclusion Criteria:

  • Smokers
  • Any chronic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00179010

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Italo Biaggioni, M.D. Vanderbilt University
  More Information

Responsible Party: Italo Biaggioni, Professor of Medicine, Vanderbilt University Identifier: NCT00179010     History of Changes
Other Study ID Numbers: 030371
Study First Received: September 13, 2005
Last Updated: February 2, 2015

Keywords provided by Italo Biaggioni, Vanderbilt University:
Blood Flow

Additional relevant MeSH terms:
Pathologic Processes
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 25, 2017